Nouvelle déclaration d'incident
No de la demande: 2022-5881
Numéro de référence du titulaire d'homologation: 2022-US-030271
Nom du titulaire (nom légal complet, aucune abbréviation): Evergreen Animal Health, LLC
Adresse: 22655 Centennial Road
Ville: Gretna
État: Nebraska
Pays: USA
Code postal /Zip: 68028
Incident chez un animal domestique
Pays: UNITED STATES
État: GEORGIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 92334-1-92413
Nom du produit: TevraPet Activate II Extra Large Dog Over 55 lbs 4 dose
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Dog / Chien
Australian Shepherd
2
Inconnu
0.17
12
lbs
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>30 min <=2 hrs / >30 min <=2 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 08-Aug-2022, two 9 week old, approximately 12 pound each, Shepherd Dog - Australian dogs, in unknown condition, with a concomitant medical condition of fleas, were administered an unknown dose (partial tube applied to each dog) of TevraPet Activate II Extra Large Dog Over 55 lbs 4 dose (Imidacloprid, Permethrin, Pyriproxyfen) via the topical route by the animal owner. This was extra label use as the treatment program was not respected (partial tube applied and patients below labeled weight of the product). Approximately 2 hours post application, the dogs began acting off (abnormal behaviour). The dogs were bathed with an unspecified baby shampoo via the topical route by the animal owner. Approximately 3 hours post application, the dogs developed grand mal seizures. Approximately 10 hours post-application (on 09-Aug-2022), the seizures continued at the time of the report. The puppies had not been evaluated by a veterinarian. Immediate veterinary evaluation was recommended. On 16-Sep-2022 follow-up was received from the owner. These two puppies died at home minutes after the report was made on 09-Aug-2022. No veterinary intervention occurred and a necropsy was not performed. The product was applied to six puppies in total with the four other puppies also developing seizures, one of which also developed a fever. These four puppies recovered within 1-2 days of exposure without medical intervention (coded as moderate severity). No further information is expected.
Mort
Assessment: The product has a wide margin of safety in dogs and is poorly absorbed across intact skin so systemic effects, like seizures and death, are not expected. Even if ingested from the application site, only mild GI upset would be anticipated. The product was misused in this case by splitting tubes intended for much larger dogs on the puppies. Permethrin can cause a paresthesia reaction (tingling sensation) which may lead to behavior changes like agitation, trembling, hiding, and vocalization. Overdose tends to cause more pronounced signs of paresthesia and severe signs are rare. Other causes should also be considered including underlying disease (flea-bite anemia, viral or parasitic infection, congenital conditions), unknown trauma, or toxin exposure. Since no veterinary evaluation or diagnostics were performed the relationship between product use and outcome is inconclusive. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.